Richard E. Morrissey
Richard E. Morrissey has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Christopher Horvath
Preclinical Development and Therapeutic Antibody Discovery, Millennium Pharmaceuticals, Cambridge, Massachusetts 02139
2 shared publicationsEileen A. Snyder
Drug Safety, Schering-Plough Research Institute, P.O. Box 32, Lafayette, New Jersey 07848-0032
2 shared publicationsJames Patrick
Drug Metabolism, Schering-Plough Corporation, Kenilworth, New Jersey 07033; and
2 shared publicationsJames S. MacDonald
Drug Safety and Metabolism, Schering-Plough Research Institute, Lafayette, New Jersey 07848-0032
2 shared publications- Ellen Evans
Drug Safety Research and Development , Pfizer Inc. , Groton , Connecticut 06340 , United States
1 shared publication Nathaniel Collins
Drug Safety, Schering-Plough Research Institute, P.O. Box 32, Lafayette, New Jersey 07848-0032
1 shared publication
Latest Publications
- Open Access
- 1 February 2002
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 65 (2) , 256-265
Porcine Toxicology Studies of SCH 58500, an Adenoviral Vector for the p53 Gene
Adenoviral vectors are being actively investigated for their potential utility in gene therapy. SCH 58500, a replication-deficient adenoviral vector, carries the normal p53 tumor suppressor gene, which is frequently mutated or absent in several human cancers. To assess the potential toxicity associated with adenoviral use, Yorkshire pigs were dosed by intravenous, intrahepatic, or local routes (subcutaneous and intradermal) to support a variety of potential clinical indications. Porcine cells were shown to support replication of wild-type human adenovirus. The nonlethal and asymptomatic dose in pigs following dosing via the intrahepatic route was greater than 3 × 108 plaque-forming units (pfu)/kg (2.2 × 1011 particles/kg), but less than 2.1 × 109 pfu/kg (1.5 × 1012 particles/kg). By the intravenous route it was 1 × 108 pfu/kg, and by the ip route it was greater than or equal to 3 × 108 pfu/kg. In a multicycle intraperitoneal study in pigs, the high dose of 3 × 108 pfu/kg caused an increased antibody and/or an inflammatory response. By the intravenous route, plaque-forming units were present in most pigs at 5 min postdose, but only in a few at 10 min postdose. No expression was found in gonadal tissue approximately 3 weeks after a single intravenous injection of 3 × 108 pfu/kg. At high intrahepatic doses (about 1.5 × 1012 particles/kg), acute cardiovascular and hemodynamic effects were found, which in subsequent studies were also present at high doses by intravenous administration. Based on these findings, careful evaluation of hemodynamic parameters in patients receiving systemic doses of SCH 58500 is warranted.
- 1 February 2002
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 65 (2) , 256-265
Open AccessPorcine Toxicology Studies of SCH 58500, an Adenoviral Vector for the p53 Gene
Adenoviral vectors are being actively investigated for their potential utility in gene therapy. SCH 58500, a replication-deficient adenoviral vector, carries the normal p53 tumor suppressor gene, which is frequently mutated or absent in several human cancers. To assess the potential toxicity associated with adenoviral use, Yorkshire pigs were dosed by intravenous, intrahepatic, or local routes (subcutaneous and intradermal) to support a variety of potential clinical indications. Porcine cells were shown to support replication of wild-type human adenovirus. The nonlethal and asymptomatic dose in pigs following dosing via the intrahepatic route was greater than 3 × 108 plaque-forming units (pfu)/kg (2.2 × 1011 particles/kg), but less than 2.1 × 109 pfu/kg (1.5 × 1012 particles/kg). By the intravenous route it was 1 × 108 pfu/kg, and by the ip route it was greater than or equal to 3 × 108 pfu/kg. In a multicycle intraperitoneal study in pigs, the high dose of 3 × 108 pfu/kg caused an increased antibody and/or an inflammatory response. By the intravenous route, plaque-forming units were present in most pigs at 5 min postdose, but only in a few at 10 min postdose. No expression was found in gonadal tissue approximately 3 weeks after a single intravenous injection of 3 × 108 pfu/kg. At high intrahepatic doses (about 1.5 × 1012 particles/kg), acute cardiovascular and hemodynamic effects were found, which in subsequent studies were also present at high doses by intravenous administration. Based on these findings, careful evaluation of hemodynamic parameters in patients receiving systemic doses of SCH 58500 is warranted.
- Open Access
- 1 February 2002
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 65 (2) , 266-275
Rodent Nonclinical Safety Evaluation Studies of SCH 58500, an Adenoviral Vector for the p53 Gene
SCH 58500 is a replication-defective recombinant adenoviral vector containing the cloned human wild-type (normal) tumor suppressor gene p53. SCH 58500 is in trials to evaluate potential clinical utility. A series of toxicology studies in rats and mice were conducted via multiple routes of exposure to support these programs. The nonlethal and asymptomatic dose in rats following a 14-day observation period was equal to 7.5 × 107 plaque-forming units (pfu)/kg (5.6 × 1010 particles/kg) by intravenous or intraperitoneal route and was similar by the ip route, following 4 weeks of dosing. The high dose of 1.5 × 109 pfu/kg (1.1 × 1012 particles/kg) was lethal by the iv route and inflammatory to the peritoneal cavity by the ip route. SCH 58500 was rapidly cleared from the systemic circulation in rats (serum t1/2 of 7 to 9 min) following iv administration. Administration by other routes resulted in no (sc) or delayed (ip) serum levels. Since most rats in the iv rat study died within 24 h postdose, another study to evaluate potential mechanisms of toxicity in rats was designed in which rats were killed at intervals following a single iv dosing. A singe high iv dose of SCH 58500 (1.1 × 1012 pfu/kg) was associated with lethargy, soft feces, a ruffled-hair coat, and death within 1 h postdose. Potential mechanisms of toxicity appeared to include a mild coagulopathy and/or vasculopathy, resulting in consumption of platelets and clotting factors, leakage or loss of intravascular fluid, hemoconcentration, electrolyte and/or fluid shifts, a moderate stress and/or inflammatory response, and a mild, direct or indirect toxic effect on liver and/or kidney tissue. These findings suggest a multifocal cause for acute lethality following iv dosing in rats.
- 1 February 2002
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 65 (2) , 266-275
Open AccessRodent Nonclinical Safety Evaluation Studies of SCH 58500, an Adenoviral Vector for the p53 Gene
SCH 58500 is a replication-defective recombinant adenoviral vector containing the cloned human wild-type (normal) tumor suppressor gene p53. SCH 58500 is in trials to evaluate potential clinical utility. A series of toxicology studies in rats and mice were conducted via multiple routes of exposure to support these programs. The nonlethal and asymptomatic dose in rats following a 14-day observation period was equal to 7.5 × 107 plaque-forming units (pfu)/kg (5.6 × 1010 particles/kg) by intravenous or intraperitoneal route and was similar by the ip route, following 4 weeks of dosing. The high dose of 1.5 × 109 pfu/kg (1.1 × 1012 particles/kg) was lethal by the iv route and inflammatory to the peritoneal cavity by the ip route. SCH 58500 was rapidly cleared from the systemic circulation in rats (serum t1/2 of 7 to 9 min) following iv administration. Administration by other routes resulted in no (sc) or delayed (ip) serum levels. Since most rats in the iv rat study died within 24 h postdose, another study to evaluate potential mechanisms of toxicity in rats was designed in which rats were killed at intervals following a single iv dosing. A singe high iv dose of SCH 58500 (1.1 × 1012 pfu/kg) was associated with lethargy, soft feces, a ruffled-hair coat, and death within 1 h postdose. Potential mechanisms of toxicity appeared to include a mild coagulopathy and/or vasculopathy, resulting in consumption of platelets and clotting factors, leakage or loss of intravascular fluid, hemoconcentration, electrolyte and/or fluid shifts, a moderate stress and/or inflammatory response, and a mild, direct or indirect toxic effect on liver and/or kidney tissue. These findings suggest a multifocal cause for acute lethality following iv dosing in rats.